No room for statins in the quest for survival benefits in small cell lung cancer

Affiliations

Editorial

Francesco Facchinetti et al. Transl Lung Cancer Res. 2018 Apr.

. 2018 Apr;7(Suppl 2):S131-S133.

doi: 10.21037/tlcr.2018.03.07.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A. Seckl MJ, et al. J Clin Oncol. 2017 May 10;35(14):1506-1514. doi: 10.1200/JCO.2016.69.7391. Epub 2017 Feb 27. J Clin Oncol. 2017. PMID: 28240967 Free PMC article. Clinical Trial.

1. Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer. N Engl J Med 2017;377:849-61. 10.1056/NEJMra1703413 - DOI - PubMed
1. Hann CL, Rudin CM. Fast, hungry and unstable: finding the Achilles’ heel of small-cell lung cancer. Trends Mol Med 2007;13:150-7. 10.1016/j.molmed.2007.02.003 - DOI - PMC - PubMed
1. Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study. J Clin Oncol 2017;35:3823-9. 10.1200/JCO.2017.72.5069 - DOI - PubMed
1. Hellmann MD, Ott PA, Zugazagoitia J, et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. J Clin Oncol 2017;35: abstr 8503.
1. Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 2017;18:42-51. 10.1016/S1470-2045(16)30565-4 - DOI - PMC - PubMed